The pharmaceutical concern begins to recommend the use of the third dose of Pfizer / BioNTech 3 mcg (microgram), intended for vaccination of children under the age of five.
Experts conclude that the two doses given to children two, three and four years old did not elicit an immune response comparable to that in adolescents and adults. On the other hand, the vaccine elicited an immune response in children between six months and two years of age.
The company said it had “found no safety issues,” and said that “the decision to recommend a third dose of a drug intended exclusively for children six months to five years of age reflects the company’s commitment to carefully choosing the right dosage to optimize benefits.”
The clinical trial will now include a third dose, to be administered at least two months after the second, with the aim of increasing protection for children under five years of age.
If the three doses are finally successful, the company announced that it will submit the test data to regulators in the first half of 2022 so that they can get urgent approval to sell their toddler vaccine.
They also announced that they plan to try a third dose of the drug, 10 mcg, intended for children aged 5 to 12. The third dose of the drug, 10 or 30 mcg, has already begun to be administered to 600 adolescents aged 12-17 years.
Testing has been linked to the emergence of the Omicron mutation and the initial findings that people taking a booster dose have a higher degree of protection.